Establishment Labs Holdings Inc. (NASDAQ: ESTA) has reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided guidance for 2026. The company's strong performance is evident in the following key metrics:
- Fourth quarter revenue reached $64.6 million, reflecting a significant increase of 45.2% from the same period in the previous year.
- The total revenue for the full year 2025 amounted to $211.1 million, marking a notable increase of 27.2% over 2024.
- Motiva U.S. revenue in the fourth quarter stood at $17.3 million, contributing to full-year U.S. revenue of $45.6 million.
- The company achieved a 79% reduction in net loss from operations, with a figure of $3.9 million for the fourth quarter, compared to a net loss of $18.7 million in the year-ago period.
- Adjusted EBITDA for the fourth quarter recorded a positive $5.5 million, marking a substantial increase compared to a loss of $13.1 million in the same period in the previous year.
- Establishment Labs reported a cash balance of $75.6 million as of December 31, 2025, reflecting an increase of $4.9 million compared to the third quarter of 2025.
- The company has provided 2026 revenue guidance in the range of $264 million to $266 million, representing an anticipated increase of 25.1% to 26.0% over 2025. Additionally, the revenue growth for 2027 is projected to be at least 25%.
Establishment Labs' CEO, Peter Caldini, expressed confidence in the company's growth and momentum, attributing it to strong demand from both surgeons and patients. He also highlighted the positive adjusted EBITDA achieved over the second half of the year, noting that the company is taking share while growing markets and expects to exceed 25% topline growth in both 2026 and 2027.
In terms of the fourth quarter 2025 financial results, total revenue stood at $64.6 million, representing a substantial increase from $44.5 million for the same period in 2024. The gross profit for the fourth quarter was $45.5 million, which accounted for 70.5% of revenue.
Furthermore, the company's cash balance on December 31, 2025, was reported as $75.6 million, reflecting a decrease of $14.8 million from December 31, 2024, and an increase of $4.9 million from the prior quarter.
Establishment Labs' reported non-GAAP financial measures, including EBITDA and adjusted EBITDA, to provide supplemental information to investors regarding its ongoing operating performance. These measures are intended to give insight into the earnings that management uses to make strategic decisions.
The market has reacted to these announcements by moving the company's shares 2.35% to a price of $67.51. Check out the company's full 8-K submission here.
